Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
The duration of hyperglycemia has been directly linked to higher rates of hepatic fibrosis progression, and this group had suboptimally controlled diabetes mellitus (DM) (a design requirement) for a longer duration prior to enrollment as compared to both the other groups. This is also reflected by the higher baseline visceral adipose tissue (VAT) to subcutaneous adipose tissue (SAT) ratio: 0.88 compared to 0.71 for liraglutide and 0.64 for sitagliptin cohorts. In spite of a higher VAT to SAT ratio, this cohort seems to have similar baseline magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) values as the other groups, which is at odds with prior evidence suggesting a significant correlation between the extent of visceral obesity in type II DM and intrahepatic lipid content.(2).